Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 1761 • ACR Convergence 2024
Juvenile Idiopathic Arthritis Genetic Risk Haplotypes: Relevance to Children of African Ancestry
Sabrina George¹, Hannah C Ainsworth², Kaiyu Jiang³, Gilad Barshad⁴, Adam He⁴, Edward Rice⁴, Carl D Langerfeld², Charles G Danko⁴ and James N Jarvis³, ¹University at Buffalo Jacobs School of Medicine, Buffalo, NY, ²Wake Forest University, Winston-Salem, NC, ³University of Washington School of Medicine, Seattle, WA, ⁴Cornell University Baker School of Veterinary Medicine, Ithaca, NY
Background/Purpose: - Numerous juvenile idiopathic arthritis (JIA) risk loci have been identified, overwhelmingly from cohorts of children of European ancestry (EA). The extent to which…
Abstract Number: 2653 • ACR Convergence 2024
Impact of Insurance on Time to Biological Drug (bDMARD) Initiation and Inactive Disease Achievement in Patients with Juvenile Idiopathic Arthritis
Elaine Yung¹, Xiaoxuan Liu², Bin Huang³, Michael Wagner¹, Minal Aundhia², Chen Chen⁴ and hermine brunner⁵, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cin, OH, ⁵Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: When uncontrolled, JIA is associated with short-term and long-term complications that affect the patient’s quality of life. A common goal of treatment is to…
Abstract Number: 0390 • ACR Convergence 2024
Treatment Effectiveness Following Switching from Initial TNF Inhibitor in Juvenile Idiopathic Arthritis
Mei-Sing Ong¹, Sarah Ringold², Melissa Mannion³, Marc Natter⁴ and Yukiko Kimura⁵, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ²Washington University, Seattle, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Boston Children's Hospital, Boston, MA, ⁵Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Although the increasing availability of biologic therapies has significantly improved outcomes for patients with JIA, a substantial proportion of patients require switching from the…
Abstract Number: 0415 • ACR Convergence 2024
Prevalence and Risk Factors of Low Bone Mineral Density in Children with Juvenile Idiopathic Arthritis
narendra bagri, Sushain Kalsotra, vandana jain, Manisha Jana, Maroof Ahmed Khan, Yashdeep Gupta and Sumit Kumar Das, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disease in children less than 16 years of age. Various factors have been suggested…
Abstract Number: 1765 • ACR Convergence 2024
CD8+ T Cells and Monocytes from Children with Macrophage Activation Syndrome Demonstrate Specific Transcriptional Changes Consistent with T Cell Activation and Expansion of Monocytes Shaped by Interferon and TLR Signaling
Susan Canny¹, Hannah DeBerg², Griffin Gessay², Ailing Lu³, Mary Eckert⁴, Andrea La Bella⁵, Hayley Waterman², Danish Nadeem², Susan Shenoi⁶, Joyce Hui-Yuen⁷, Daniel Campbell², Betsy Barnes⁸ and Jessica Hamerman², ¹University of Washington, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³Northwell Health, Manhasset, NY, ⁴Seattle Children's Hospital, Seattle, WA, ⁵Cohen Children's Medical Center, Queens, NY, ⁶Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, ⁷North Shore LIJ Health System, Great Neck, NY, ⁸Feinstein Institutes for Medical Science, Manhasset, NY
Background/Purpose: Macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (sHLH), is a potentially fatal complication of rheumatic diseases. MAS is characterized by a…
Abstract Number: 0392 • ACR Convergence 2024
Evaluation for the Presence of Antibodies to Malondialdehyde-Acetaldehyde Adduct in Juvenile Idiopathic Arthritis and Its Subtypes
Geoffrey Thiele¹, Panteha Hayati Rezvan², Michal Cidon², Carlos Hunter³, Michael Duryee³, Ted Mikuls³ and Geoffrey Thiele³, ¹Children's Hospital of Los Angeles, Omaha, NE, ²Children's Hospital of Los Angeles, Los Angeles, CA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Studies of rheumatoid arthritis (RA) have shown that malondialdehyde-acetaldehyde (MAA) protein adducts and anti-MAA immune responses play a pathogenic role in disease progression. Expression of…
Abstract Number: 0416 • ACR Convergence 2024
Proteomic Signatures of Synovial Fluid in Different Subtypes of Juvenile Idiopathic Arthritis
narendra bagri¹, saumya srivastava², yogendra singh², Thirumurthy Velpandian², Ashish Upadhyay², venkatesan sampath kumar², Subhradip Karmakar² and sushil K Kabra², ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²AIIMS New Delhi, new delhi, India
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is heterogenous group of inflammatory disorder with clinically distinct subtypes; polyarticular, oligoarticular systemic onset JIA (sJIA), and enthesitis-related arthritis (ERA).…
Abstract Number: 1768 • ACR Convergence 2024
A Potential Role of Longstanding IL-18 Stimulation in the Susceptibility for Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis
Greta Rogani¹, Remco Erkens¹, Marein Putmans¹, Rianne Scholman¹, Jorg van Loosdregt² and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²University Medical Center Utrecht, La Jolla, CA
Background/Purpose: Macrophage Activation Syndrome (MAS) is a pathologic condition of immune hyperactivation, which occurs in 10-30% of cases of Still’s Disease (SD), the spectrum of…
Abstract Number: 0394 • ACR Convergence 2024
Unveiling Major Challenges and Unmet Needs in the Therapeutic Approach to Systemic Juvenile Idiopathic Arthritis: The Patient Perspective
Francesco Baldo¹, Luciana Peixoto², Remco Erkens³, Greta Rogani³, Claudia Bracaglia⁴, Dirk Foell⁵, Marco Gattorno⁶, Marija Jelusic⁷, Sebastiaan Vastert³, Rashmi Sinha² and Francesca Minoia⁸, and on behalf of the PReS MAS/sJIA Working Party and the Systemic JIA Foundation, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ²Systemic JIA Foundation, Cincinnati, OH, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵University Hospital Muenster, Muenster, Germany, ⁶IRCCS Giannina Gaslini, Genoa, Italy, ⁷University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ⁸Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy
Background/Purpose: Despite continuous improvements in the therapeutic options for children with systemic juvenile idiopathic arthritis (sJIA), access to medications significantly differs among centres and countries.…
Abstract Number: 0419 • ACR Convergence 2024
Placental Weights of Offspring Born to Women with Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
Eugenia Chock¹, Zeyan Liew², Lars Henning Pedersen³ and Mette Oestergaard Thunbo³, ¹Yale School of Medicine, New Haven, CT, ²Yale Center for Perinatal, Pediatric and Environmental Epidemiology, New Haven, CT, ³Aarhus University, Aarhus, Denmark
Background/Purpose: Offspring of patients with chronic inflammatory arthritis have almost double the risk of being born small for gestational age. Placental insufficiency is one of…
Abstract Number: 1778 • ACR Convergence 2024
A Novel Variant in IRAK2 Results in Immune Dysregulation in Systemic Juvenile Idiopathic Arthritis (sJIA)
Mariana Correia Marques¹, Brooke Boyd², Alana Platukus³, Elizabeth Schmitz², Hiroto Nakano², Faiza Naz⁴, Anthony Cruz¹, Stefania Dell'Orso⁴, Zuoming deng⁴ and Michael Ombrello⁵, ¹National Institutes of Health, Bethesda, MD, ²Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ³1Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Lung disease (LD) is poorly understood complication of Still’s disease with high fatality. HLA-DRB1*15 is a strong risk factor for the development of this…
Abstract Number: 0376 • ACR Convergence 2024
Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry
Gaelle Chedeville¹, Heinrike Schmeling², Jean-Philippe Proulx-Gauthier³, Michelle Batthish⁴, Jean Jacques De Bruycker⁵, Brian Feldman⁶, Roberta A Berard⁷, Roxana Bolaria⁸, Amieleena Chhabra⁹, Lily Lim¹⁰, Adam Huber¹¹, Matthew Berkowitz¹², Thomas Loughin¹² and Jaime Guzman¹³, and CAPRI Registry Investigators, ¹The Montreal Children's Hospital, Montreal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³CHU de Quebec - Universite Laval, Quebec, QC, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵UNIVERSITY OF MONTREAL, Montreal, QC, Montreal, QC, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁷London Health Sciences Centre, London, ON, Canada, ⁸Victoria Arthritis Center, Victoria, BC, Canada, ⁹University of British Columbia, Penticton, BC, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹IWK Health Centre, Halifax, NS, Canada, ¹²Simon Fraser University, Burnaby, BC, Canada, ¹³University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: About 50% of children with Juvenile Idiopathic Arthritis (JIA) receiving methotrexate (MTX) develop MTX intolerance with severe anticipatory nausea/vomiting and avoidance behaviors. Intolerance often…
Abstract Number: 0395 • ACR Convergence 2024
Assessment of Enthesitis by Pediatric Rheumatology Providers
Erin Treemarcki¹, Shirley Tse², Marisa Klein-Gitelman³, Adam Mayer⁴, Hemalatha Srinivasalu⁵, Heather Walters⁶ and Melissa Oliver⁷, and the CARRA Juvenile Spondyloarthritis Workgroup and the CARRA investigators, ¹University of Utah, Salt Lake City, UT, ²SickKids, Toronto, ON, Canada, ³Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Children's National Hospital, Washington, DC, ⁶Northwell Health, New Hyde Park, NY, ⁷Indiana University, Indianapolis, IN
Background/Purpose: Enthesitis is a characteristic feature of enthesitis related arthritis (ERA) but can be found in other juvenile idiopathic arthritis (JIA) subtypes. It occurs with…
Abstract Number: 0779 • ACR Convergence 2024
Sex Differences in the B Cell Compartment of Patients with Oligoarticular Juvenile Idiopathic Arthritis
Ki Pui Lam¹, Claudia Harris¹, Daniela Fernandez-Salinas¹, Maryrose Hahn², Maryam Ashoor³, Ahmad Bakhsh¹, Carrie Bryant¹, Siobhan Case¹, Mia Chandler⁴, Joyce Chang⁵, Ezra Cohen¹, Fatma Dedeoglu³, Olha Halyabar¹, Jonathan Hausmann¹, Melissa Hazen³, Daniel Ibanez¹, Liyoung Kim¹, Jeffrey Lo³, Mindy Lo³, Esra Meidan⁶, Megan Perron¹, Helene Powers¹, Mary Beth Son⁵, Holly Wobma⁷, Pui Lee⁸, Peter Nigrovic⁵, Laurie Ohlms⁹, Margaret Chang³, Maria Gutierrez-Arcelus³ and Lauren Henderson¹⁰, ¹Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Boston Children's Hospital, Georgetown, MA, ³Boston Children's Hospital, boston, MA, ⁴Boston Children’s Hospital, Boston, MA, ⁵Boston Children's Hospital, Brookline, MA, ⁶Boston Children's Hospital, Somerville, MA, ⁷Division of Immunology, Boston Children's Hospital, Boston, MA, ⁸Boston Children's Hospital, Newton, MA, ⁹Department of Otolaryngology & Communication Enhancement, Boston Children’s Hospital, Harvard Medical School, Boston, MA, ¹⁰Boston Children's Hospital, Watertown, MA
Background/Purpose: T peripheral helper (Tph) cells accumulate in the joints of children with ANA+ oligoarticular juvenile idiopathic arthritis (oligo JIA) and may provide pathogenic help…
Abstract Number: 1782.5 • ACR Convergence 2024
Monocytes from HLA B27 Positive Enthesitis Related Arthritis Patients Are More Activated Than HLA B27 Negative Patients
Shivika Guleria¹, Anu Balakrishnan¹, Able Lawrence¹ and Amita Aggarwal², ¹SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

Background/Purpose: Enthesitis related arthritis (ERA) is a chronic immune-inflammatory disease with unknown etiology. HLA-B27 is the strongest risk factor predisposing to ERA similar to Spondylarthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].